Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.

@article{Katayama2007ReductionON,
  title={Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.},
  author={Takuji Katayama and Hiroto Ueba and Ken Tsuboi and Norifumi Kubo and Takanori Yasu and Masatoshi Kuroki and Muneyasu Saito and Shin-ichi Momomura and Masanobu Kawakami},
  journal={American heart journal},
  year={2007},
  volume={153 5},
  pages={762.e1-7}
}
BACKGROUND This study investigates whether pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with metabolic syndrome (MS) using intravascular ultrasound (IVUS). Pioglitazone, a novel insulin-sensitizing thiazolidinedione, has been shown to reduce neointimal hyperplasia after coronary stenting in patients with type 2 diabetes. However, the effect of pioglitazone on in-stent restenosis in nondiabetic patients with MS remains unknown. METHODS AND RESULTS… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…